Literature DB >> 35351534

White Coat Hypertension Persistence in Children and Adolescents: The Pediatric Nephrology Research Consortium Study.

Yosuke Miyashita1, Coral Hanevold2, Anna Faino3, Julia Scher4, Marc Lande4, Ikuyo Yamaguchi5, Joel Hernandez6, Alisa Acosta7, Donald J Weaver8, Jason Thomas9, Mahmoud Kallash10, Michael Ferguson11, Ketan N Patel12, Andrew M South13, Megan Kelton2, Joseph T Flynn2.   

Abstract

OBJECTIVES: To determine whether youth with white coat hypertension on initial ambulatory blood pressure monitoring (ABPM) continue to demonstrate the same pattern on repeat ABPM. STUDY
DESIGN: Retrospective longitudinal cohort study of patients referred for high blood pressure (BP) and diagnosed with white coat hypertension by ABPM who had follow-up ABPM 0.5-4.6 years later at 11 centers in the Pediatric Nephrology Research Consortium. We classified ABPM phenotype using the American Heart Association guidelines. At baseline, we classified those with hypertensive BP in the clinic as "stable white coat hypertension," and those with normal BP as "intermittent white coat hypertension." We used multivariable generalized linear mixed effect models to estimate the association of baseline characteristics with abnormal ABPM phenotype progression.
RESULTS: Eighty-nine patients met the inclusion criteria (median age, 13.9 years; 78% male). Median interval time between ABPM measurements was 14 months. On follow-up ABPM, 61% progressed to an abnormal ABPM phenotype (23% ambulatory hypertension, 38% ambulatory prehypertension). Individuals age 12-17 years and those with stable white coat hypertension had greater proportions progressing to either prehypertension or ambulatory hypertension. In the multivariable models, baseline wake systolic BP index ≥0.9 was significantly associated with higher odds of progressing to ambulatory hypertension (OR 3.07, 95% CI 1.02-9.23).
CONCLUSIONS: The majority of the patients with white coat hypertension progressed to an abnormal ABPM phenotype. This study supports the 2017 American Academy of Pediatrics Clinical Practice Guideline's recommendation for follow-up of ABPM in patients with white coat hypertension.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ambulatory blood pressure monitoring

Mesh:

Year:  2022        PMID: 35351534      PMCID: PMC9275430          DOI: 10.1016/j.jpeds.2022.03.036

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   6.314


  32 in total

1.  The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents.

Authors: 
Journal:  Pediatrics       Date:  2004-08       Impact factor: 7.124

2.  Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents.

Authors:  Joseph T Flynn; David C Kaelber; Carissa M Baker-Smith; Douglas Blowey; Aaron E Carroll; Stephen R Daniels; Sarah D de Ferranti; Janis M Dionne; Bonita Falkner; Susan K Flinn; Samuel S Gidding; Celeste Goodwin; Michael G Leu; Makia E Powers; Corinna Rea; Joshua Samuels; Madeline Simasek; Vidhu V Thaker; Elaine M Urbina
Journal:  Pediatrics       Date:  2017-08-21       Impact factor: 7.124

Review 3.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright
Journal:  J Am Coll Cardiol       Date:  2017-11-13       Impact factor: 24.094

4.  Reproducibility of Office and Out-of-Office Blood Pressure Measurements in Children: Implications for Clinical Practice and Research.

Authors:  George S Stergiou; Ioanna Bountzona; Christina Alamara; Andriani Vazeou; Anastasios Kollias; Angeliki Ntineri
Journal:  Hypertension       Date:  2021-01-11       Impact factor: 10.190

5.  Assessment of target-organ damage in adolescent white-coat and sustained hypertensives.

Authors:  Dénes Páll; Mária Juhász; Szabolcs Lengyel; Csilla Molnár; György Paragh; Béla Fülesdi; Eva Katona
Journal:  J Hypertens       Date:  2010-10       Impact factor: 4.844

Review 6.  White-coat hypertension, as defined by ambulatory blood pressure monitoring, and subclinical cardiac organ damage: a meta-analysis.

Authors:  Cesare Cuspidi; Marta Rescaldani; Marijana Tadic; Carla Sala; Guido Grassi; Giuseppe Mancia
Journal:  J Hypertens       Date:  2015-01       Impact factor: 4.844

7.  White-coat and masked hypertension in children: association with target-organ damage.

Authors:  Stella Stabouli; Vasilios Kotsis; Savvas Toumanidis; Christos Papamichael; Andreas Constantopoulos; Nikos Zakopoulos
Journal:  Pediatr Nephrol       Date:  2005-06-10       Impact factor: 3.714

8.  Cost-effectiveness of ambulatory blood pressure monitoring in the initial evaluation of hypertension in children.

Authors:  Sarah J Swartz; Poyyapakkam R Srivaths; Beth Croix; Daniel I Feig
Journal:  Pediatrics       Date:  2008-12       Impact factor: 7.124

Review 9.  White-coat hypertension and cardiovascular events: a meta-analysis.

Authors:  Alexandros Briasoulis; Emmanuel Androulakis; Mohan Palla; Nikolaos Papageorgiou; Dimitris Tousoulis
Journal:  J Hypertens       Date:  2016-04       Impact factor: 4.844

10.  Left ventricular mass index in children with white coat hypertension.

Authors:  Marc B Lande; Cecilia C Meagher; Susan Gross Fisher; Puneet Belani; Hongyue Wang; Megan Rashid
Journal:  J Pediatr       Date:  2008-03-19       Impact factor: 4.406

View more
  1 in total

1.  White coat hypertension during the SARS-CoV-2 pandemic.

Authors:  Kaveh Nasiri; Aleksandra Dimitrova; Karl-Thomas Wrbas
Journal:  J Dent Sci       Date:  2022-10-05       Impact factor: 3.719

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.